SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

UroGen Pharma Q3 Revenue $89.001 Million vs. IBES Estimate $89.9 Million

Story updates

01:10:51 PM UTC
SquawkNews
UroGen Pharma Q3 revenue misses expectations on JELMYTO decline

Related stories